The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A combination chemotherapy, temozolomide (TMZ) with etoposide (VP), in relapsed or refractory pediatric solid cancer: Preliminary report of randomized phase II study of two different outpatient setting regimens (rPII).
Atsushi Ogawa
No relevant relationships to disclose
Hiroshi Kawamoto
No relevant relationships to disclose
Mari Saito Oba
No relevant relationships to disclose
Ako Hosono
No relevant relationships to disclose
Yoshiyuki Kosaka
No relevant relationships to disclose
Junichi Hara
No relevant relationships to disclose
Yuji Ishida
No relevant relationships to disclose
Kenji Yamada
No relevant relationships to disclose
Katsuyoshi Koh
No relevant relationships to disclose
Yasuhiro Okamoto
No relevant relationships to disclose
Hideo Mugishima
No relevant relationships to disclose
Atsushi Kikuta
No relevant relationships to disclose
Takashi Taga
No relevant relationships to disclose